Total
0
Shares
Epsilon Healthcare’s (ASX:EPN) Tetra Health launches face-to-face clinic
Market Herald logo

Subscribe

Be the first with the news that moves the market
  • Cann Global (CGB) has entered a binding agreement with Western Sydney University’s NICM Health Research Institute
  • The company is currently evaluating the efficacy of a unique strain of medicinal cannabis to slow the progression of multiple sclerosis (MS)
  • Under the agreement, the parties will design a clinical trial protocol for the purpose of undertaking human clinical trials in Australia
  • On the market today, Cann is up 21.4 per cent and is trading at 0.9 cents per share

Cann Global (CGB) has entered a binding agreement with Western Sydney University’s NICM Health Research Institute.

The company is currently evaluating the efficacy of a unique strain of medicinal cannabis to slow the progression of multiple sclerosis (MS).

Under the agreement, the parties will design a clinical trial protocol for the purpose of undertaking human clinical trials in Australia.

Last year, Cann saw successful research results in Israel, where research led by Dr Dedi Meiri found that a unique cannabis strain in mice trials stopped the progression of MS and, in some cases, significantly reversed the damage caused by MS.

In February, Cann Global announced that the human clinical trials for this research would be continued in Australia, as clinical data and results are recognised worldwide due to the high standard of research.

NICM Health Research Institute is Australia’s leader in integrative and complementary medicine research and policy.

"Cann will update the market with the expected timetable for implementation
of the clinical trials once the protocol has been designed," Cann told the market today.

On the market today, Cann is up 21.4 per cent and is trading at 0.9 cents per share at 11:27 am AEST.

CGB by the numbers
More From The Market Herald
Rhythm Biosciences (ASX:RHY) - CEO, Glenn Gilbert - The Market Herald

" Rhythm Biosciences (ASX:RHYS) adds Sonic Clinical Services to ColoSTAT clinical trial

Rhythm Biosciences (RHY) has added the primary care division of medical giant Sonic Healthcare (SHL) to its ColoSTAT clinical trial.
Orthocell (ASX:OCC) - CEO Paul Anderson with intern Margeux Steltz - The Market Herald

" Orthocell (ASX:OCC) secures Chinese and NZ patents

Regenerative medicine company Orthocell (OCC) has secured Chinese and New Zealand patents for its novel CelGro collagen medical device for soft tissue regeneration.
Patrys (ASX:PAB) - - The Market Herald

" Study finds Patrys’ (ASX:PAB) candidate could slow brain cancer

A new study featuring Patrys’ (PAD) PAT-DX1 candidate has demonstrated its ability to inhibit the growth of primary and secondary brain cancers.
Avita Medical (ASX:AVH) - CEO, Mike Perry - The Market Herald

" Avita Medical (ASX:AVH) boosts fourth-quarter revenue forecast

With the prevailing strength of its RECELL System, Avita Medical (AVH) has elected to increase its fourth-quarter revenue guidance.